MTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2

Nature Communications

Volumn 7, Issue , 2016, Pages

  Kim, Kyeongjin ^a   Qiang, Li ^a   Hayden, Matthew S ^a   Sparling, David P ^a   Purcell, Nicole H ^b   Pajvani, Utpal B ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHOPROTEIN PHOSPHATASE 2; PLECKSTRIN; PROTEIN KINASE B; TRIACYLGLYCEROL; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; GLUCOSE BLOOD LEVEL; INSULIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; ONCOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE; RPTOR PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

AGE; LIPID; OBESITY; RAPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAPTOR; YOUNG ADULT; ANIMAL; FATTY LIVER; GENETICS; GLUCOSE BLOOD LEVEL; IMMUNOPRECIPITATION; LIPID DIET; LIVER; LIVER CELL; METABOLISM; OBESITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIZE EXCLUSION CHROMATOGRAPHY; WESTERN BLOTTING;

MUS; RAPTORES;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; BLOOD GLUCOSE; BLOTTING, WESTERN; CHROMATOGRAPHY, GEL; DIET, HIGH-FAT; FATTY LIVER; HEPATOCYTES; IMMUNOPRECIPITATION; INSULIN; LIPOGENESIS; LIVER; MICE; MULTIPROTEIN COMPLEXES; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; ONCOGENE PROTEIN V-AKT; PHOSPHOPROTEIN PHOSPHATASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES;

EID: 84953932016     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10255     Document Type: Article

References (56)

1. Ford, E. S., Giles, W. H. & Dietz, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
2. Villanova, N. et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42, 473-480 (2005).
3. Dowman, J. K., Armstrong, M. J., Tomlinson, J. W. & Newsome, P. N. Current therapeutic strategies in non-Alcoholic fatty liver disease. Diabetes Obes. Metab. 13, 692-702 (2011).
4. Slawik, M. & Vidal-Puig, A. J. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res. Rev. 5, 144-164 (2006).
5. Howell, J. J. & Manning, B. D. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol. Metab. 22, 94-102 (2011).
6. Peterson, T. R. et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146, 408-420 (2011).
7. Porstmann, T. et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8, 224-236 (2008).
8. Brown, N. F., Stefanovic-Racic, M., Sipula, I. J. & Perdomo, G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 56, 1500-1507 (2007).
9. Yecies, J. L. et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14, 21-32 (2011).
10. Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Molecular cell 39, 171-183 (2010).
11. Yabe, D., Brown, M. S. & Goldstein, J. L. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc. Natl Acad. Sci. USA 99, 12753-12758 (2002).
12. Yabe, D., Komuro, R., Liang, G., Goldstein, J. L. & Brown, M. S. Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc. Natl Acad. Sci. USA 100, 3155-3160 (2003).
13. Li, S., Brown, M. S. & Goldstein, J. L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl Acad. Sci. USA 107, 3441-3446 (2010).
14. Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85-96 (2006).
15. Lu, M. et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18, 388-395 (2012).
16. Lin, H. V. & Accili, D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 14, 9-19 (2011).
17. Haas, J. T. et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 15, 873-884 (2012).
18. Stephens, L. et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279, 710-714 (1998).
19. Leslie, N. R., Biondi, R. M. & Alessi, D. R. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem. Rev. 101, 2365-2380 (2001).
20. Yuan, M., Pino, E., Wu, L., Kacergis, M. & Soukas, A. A. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J. Biol. Chem. 287, 29579-29588 (2012).
21. Hagiwara, A. et al. Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c. Cell Metab. 15, 725-738 (2012).
22. Mora, A., Lipina, C., Tronche, F., Sutherland, C. & Alessi, D. R. Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem. J. 385, 639-648 (2005).
23. Pajvani, U. B. et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat. Med. 19, 1054-1060 (2013).
24. Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175 (2002).
25. Gao, T., Furnari, F. & Newton, A. C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18, 13-24 (2005).
26. Brognard, J., Sierecki, E., Gao, T. & Newton, A. C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25, 917-931 (2007).
27. Menon, S. et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156, 771-785 (2014).
28. Kim, S. et al. Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. Cell Metab. 13, 215-221 (2011).
29. Sengupta, S., Peterson, T. R., Laplante, M., Oh, S. & Sabatini, D. M. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468, 1100-1104 (2010).
30. Yip, C. K., Murata, K., Walz, T., Sabatini, D. M. & Kang, S. A. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol. Cell 38, 768-774 (2010).
31. Jain, A. et al. Stoichiometry and assembly of mTOR complexes revealed by single-molecule pulldown. Proc. Natl Acad. Sci. USA 111, 17833-17838 (2014).
32. Kim, D. H. et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11, 895-904 (2003).
33. Cook, J. R. et al. A mutant allele encoding DNA binding-deficient FoxO1 differentially regulates hepatic glucose and lipid metabolism. Diabetes 64, 1951-1965 (2015).
34. Wang, J. et al. Effects of adenovirus-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo. Diabetes Obes. Metab. 3, 367-380 (2001).
35. Facchinetti, V. et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27, 1932-1943 (2008).
36. Ikenoue, T., Inoki, K., Yang, Q., Zhou, X. & Guan, K. L. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27, 1919-1931 (2008).
37. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
38. Li, X., Liu, J. & Gao, T. beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol. Cell. Biol. 29, 6192-6205 (2009).
39. Calvisi, D. F. et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140, 1071-1083 (2011).
40. Li, L. et al. SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice. PLoS ONE 8, e75104 (2013).
41. Ono, H. et al. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52, 2905-2913 (2003).
42. Kaizuka, T. et al. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J. Biol. Chem. 285, 20109-20116 (2010).
43. Michael, M. D. et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6, 87-97 (2000).
44. Dong, X. C. et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 8, 65-76 (2008).
45. Haeusler, R. A. et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat. Commun. 5, 5190 (2014).
46. Newton, A. C. & Trotman, L. C. Turning off AKT: PHLPP as a drug target. Annu. Rev. Pharmacol. Toxicol. 54, 537-558 (2014).
47. Brognard, J., Niederst, M., Reyes, G., Warfel, N. & Newton, A. C. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. J. Biol. Chem. 284, 15215-15223 (2009).
48. Bradley, E. W., Carpio, L. R. & Westendorf, J. J. Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion. J. Biol. Chem. 288, 9572-9582 (2013).
49. Gao, M. H., Miyanohara, A., Feramisco, J. R. & Tang, T. Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6. Biochem. Biophys. Res. Commun. 384, 193-198 (2009).
50. Andreozzi, F. et al. Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance. Diabetologia 54, 1879-1887 (2011).
51. Cozzone, D. et al. Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia 51, 512-521 (2008).
52. Mishra, N. et al. Efficient hepatic delivery of drugs: novel strategies and their significance. Biomed. Res. Int. 2013, 382184 (2013).
53. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497-509 (1957).
54. Zhang, Y. L. et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J. Biol. Chem. 281, 37603-37615 (2006).
55. Miyamoto, S. et al. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ. Res. 107, 476-484 (2010).
56. Kim, K., Pyo, S. & Um, S. H. S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-Activated receptor alpha activity in the liver. Hepatology 55, 1727-1737 (2012).